Results 21 to 30 of about 93,800 (248)

Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody

OncoImmunology, 2019
Depletion of T regulatory cells (Tregs) in the tumor microenvironment is a promising cancer immunotherapy strategy. Current approaches for depleting Tregs are limited by lack of specificity and concurrent depletion of anti-tumor effector T cells.
Tao Dao, Sung Soo Mun, Andrew C. Scott, Casey A. Jarvis, Tatyana Korontsvit, Zhiyuan Yang, Lianxing Liu, Martin G. Klatt, Manuel Guerreiro, Annamalai Selvakumar, Elliott J. Brea, Claire Oh, Cheng Liu, David A. Scheinberg   +13 more
doaj   +1 more source

MSC-Derived Small Extracellular Vesicles Attenuate Autoimmune Dacryoadenitis by Promoting M2 Macrophage Polarization and Inducing Tregs via miR-100-5p

Frontiers in Immunology, 2022
BackgroundMesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) have been increasingly proved as promising immunomodulators against some autoimmune disorders.
Na Li, Zhiqi Gao, Lu Zhao, Bei Du, Binyun Ma, Hong Nian, Ruihua Wei   +6 more
doaj   +1 more source

MALAT1 Induces Food Allergy by Promoting Release of IL-6 from Dendritic Cells and Suppressing the Immunomodulatory Function of Tregs

Journal of Asthma and Allergy, 2022
Hua Feng,1,2 Xiujuan Xiong,3 Zhuo Chen,1 Nan Luo,2 Yongning Wu1,4,5 1State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, 330000, People’s Republic of China; 2School of Public Health, Nanchang University, Nanchang, 330006 ...
Feng H, Xiong X, Chen Z, Luo N, Wu Y
doaj  

Targeting crosstalk of STAT3 between tumor-associated M2 macrophages and Tregs in colorectal cancer

Cancer Biology & Therapy, 2023
A comprehensive analysis of the molecular mechanism underlying colorectal tumor evaluated the development of colorectal cancer (CRC) and proposed targeting small molecular inhibitors.
Lili Huang, Yu Zhao, Mengying Shan, Sitong Wang, Jianhua Chen, Zhuqing Liu, Qing Xu   +6 more
doaj   +1 more source

GP96: safeguarding Treg

Oncotarget, 2015
FOXP3 positive regulatory T cells (Tregs) are key players in maintaining peripheral immune tolerance. Multiple molecules and signaling pathways are involved in regulating Treg function. Understanding these mechanisms is vital to designing Treg-targeted immunotherapeutic strategies for cancer and other diseases. A recent study uncovered that endoplasmic
Yongliang, Zhang, Ephraim, Ansa-Addo, Zihai, Li   +2 more
openaire   +2 more sources

Increased Plasticity of FOXP3+ Treg under Pathological Conditions Convert Treg into Either Novel Treg or Th1‐Treg

The FASEB Journal, 2018
Naïve CD4+ Th (T helper cells) can differentiate/be polarized in to 9 terminally differentiated Th cell subsets depending on the cytokine repertoire and anatomical location. CD4+ FOXP3+ (forkhead box P3) regulatory T cells (Treg) are one of the Th subsets.
Keman Xu, William Y. Yang, Gayani K. Nanayakkara, Ying Shao, Fan Yang, Wenhui Hu, Eric T. Choi, Hong Wang, Xiaofeng Yang   +8 more
openaire   +1 more source

The essential schistosome tegumental ectoenzyme SmNPP5 can block NAD-induced T cell apoptosis

Virulence, 2020
Infection with intravascular platyhelminths of the genus Schistosoma can result in the debilitating disease schistosomiasis. Schistosomes (blood flukes) can survive in the host for many years.
Catherine S. Nation, Akram A. Da’Dara, Patrick J. Skelly   +2 more
doaj   +1 more source

RETRACTED: Tregs depletion aggravates activation of astrocytes by modulating IL-10/GXP4 following cerebral infarction

Frontiers in Immunology, 2023
BackgroundTregs plays a critical role in the development of secondary injuries in diseases. Accumulating evidence suggests an association between ischemic stroke and renal dysfunction; however, the underlying mechanisms remain unclear.
Shuai Wang, Yubin Shi, Yanqi Zhang, Fengyun Yuan, Mintao Mao, Jun Ma   +5 more
doaj   +1 more source

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4⁺ T Cells

Vaccines, 2019
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and it exhibits resistance to common breast cancer therapies. Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and its ligand, PD-L1, have been
Reem Saleh, Salman M Toor, Sarah Khalaf, Eyad Elkord   +3 more
doaj   +1 more source

Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients

OncoImmunology, 2020
The immune modulatory effect of tivozanib, a tyrosine kinase inhibitor, and the underlying immune mechanisms impacting survival of HCC patients have not been investigated.
Suresh Gopi Kalathil, Katy Wang, Alan Hutson, Renuka Iyer, Yasmin Thanavala   +4 more
doaj   +1 more source